Share Twitter LinkedIn Facebook Email Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, regarding the role of proteasome inhibitors in maintenance therapy for multiple myeloma patients.
53 vs 31 Month Isatuximab-VRD Results: My Interview with SANOFI’s Global Product Head at ASCO 2024 ASCO Annual Meeting 2 Mins Read